Annuncio pubblicitario
Italia markets close in 1 hour 26 minutes
  • FTSE MIB

    33.900,18
    +270,97 (+0,81%)
     
  • Dow Jones

    38.797,51
    +121,83 (+0,32%)
     
  • Nasdaq

    16.255,05
    +98,73 (+0,61%)
     
  • Nikkei 225

    38.236,07
    -38,03 (-0,10%)
     
  • Petrolio

    78,70
    +0,59 (+0,76%)
     
  • Bitcoin EUR

    59.370,21
    +19,51 (+0,03%)
     
  • CMC Crypto 200

    1.376,31
    +63,68 (+4,85%)
     
  • Oro

    2.336,30
    +27,70 (+1,20%)
     
  • EUR/USD

    1,0786
    +0,0020 (+0,18%)
     
  • S&P 500

    5.156,30
    +28,51 (+0,56%)
     
  • HANG SENG

    18.578,30
    +102,38 (+0,55%)
     
  • Euro Stoxx 50

    4.948,41
    +26,93 (+0,55%)
     
  • EUR/GBP

    0,8571
    -0,0007 (-0,08%)
     
  • EUR/CHF

    0,9758
    +0,0024 (+0,24%)
     
  • EUR/CAD

    1,4722
    -0,0002 (-0,02%)
     

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Autolus Therapeutics plc
Autolus Therapeutics plc

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023.

Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

ANNUNCIO PUBBLICITARIO

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com